Business Wire

SV Life Sciences Managers LLP, Manager of Dementia Discovery Fund (DDF) Appoints World-Renowned Chief Scientific Officer to Lead the New DDF Investment Team

Del

The Dementia Discovery Fund (DDF) www.TheDDFund.com, an innovative global investment fund launched in October 2015 to discover and develop new disease modifying drugs for dementia, announces the appointment of Tetsuyuki Maruyama PhD as its Chief Scientific Officer.

Dr Tetsuyuki Maruyama will join the DDF in April 2016 from Takeda Pharmaceutical Co. Ltd where for the past five years he has been Senior VP, General Manager, Pharmaceutical Research Division, leading global drug discovery after his initial appointment as Head of CNS Research. Prior to this he was Director of GlaxoSmithKline Plc’s neuroscience research centre in Singapore, and led Alzheimer’s Disease target discovery efforts at Merck Sharpe & Dohme, Ltd. Dr Maruyama has lectured in neuroscience at Yale University, the University of Minnesota, the University of Edinburgh, and Cardiff University, where he was Professor in the Cardiff School of Biosciences. Dr Maruyama’s research has been published in the world’s leading scientific journals (under his previous name, Paul Chapman).

In addition, Dr Laurence Barker will join the DDF as Chief Business Officer in February 2016 from GlaxoSmithKline Plc where he has been Head of Investment Management, Worldwide Business Development. He has previously held business development roles at Syntaxin Ltd and MorphoSys AG and has an MBA from the University of Cambridge.

Barbara Tate joined the DDF as Venture Partner in Boston following the successful $485m deal between Biogen and Rodin – which she helped start with Atlas Venture. Dr Tate was previously Senior Director of Neuroscience at Pfizer following her long successful academic career at Harvard and Brown.

Dr Maruyama, Dr Barker, Dr Tate all join Dr Carol Routledge who joined the DDF in September 2015. Dr Routledge was previously Head of Translational Medicine, Biopharm Discovery, GSK, following 30 years of neuroscience drug discovery and development experience from prior roles at GSK, Syntex, Wyeth and BTG.

Kate Bingham, Managing Partner at SV Life Sciences Managers LLP, manager of the DDF, said: “The assembly of such a high calibre DDF team so soon after the Fund’s launch demonstrates the interest in this field and belief in what this Fund can deliver. Tetsu’s experience in global discovery, both in big pharma and academia, is exceptional and we look forward to welcoming him and Laurence soon.”

Tetsuyuki Maruyama, Chief Scientific Officer of the DDF, added: “The DDF has the mission to change the approach, diagnosis and treatment of dementia and I am pleased to be joining such a strong team who have already made significant progress since launch towards this ambitious goal.”

For further information please visit the DDF website at www.theddfund.com

About the Dementia Discovery Fund

The DDF is an innovative global investment fund established in October 2015 to deliver new disease modifying drugs for dementia by 2025. Managed by SV Life Sciences Managers LLP, DDF investors include the UK Government’s Department of Health, Alzheimer’s Research UK and world-leading major pharmaceutical companies: Biogen, GlaxoSmithKline, Johnson & Johnson, Lilly, Pfizer and Takeda. The DDF works collaboratively with universities, academic institutes, government, the regulatory agencies and the biotechnology and pharmaceutical industry internationally to identify and develop novel dementia research projects.

About SV Life Sciences Managers LLP

SV Life Sciences Managers manages life sciences investments for both the Dementia Discovery Fund (www.TheDDFund.com) and the publicly listed fund International Biotechnology Trust plc (www.ibtplc.com). The investment team have a breadth of experience across both public and private investing.

THIS ANNOUNCEMENT IS NOT FOR PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA. THIS ANNOUNCEMENT IS NOT AN OFFER OF SECURITIES FOR SALE INTO THE UNITED STATES. THE SECURITIES REFERRED TO HEREIN HAVE NOT BEEN AND WILL NOT BE REGISTERED UNDER THE U.S. SECURITIES ACT OF 1933, AS AMENDED, AND MAY NOT BE OFFERED OR SOLD IN THE UNITED STATES, EXCEPT PURSUANT TO AN APPLICABLE EXEMPTION FROM REGISTRATION. NO PUBLIC OFFERING OF SECURITIES IS BEING MADE IN THE UNITED STATES.

Contact information

Dementia Discovery Fund
Carol Routledge, +44 20 7421 7091
Venture Partner
carol.routledge@svlsm.com
or
Consilium Strategic Communications
Mary-Jane Elliott, Chris Gardner, Amber Fennell, Ivar Milligan
+44 20 3709 5700
DDF@consilium-comms.com

Om Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Følg saker fra Business Wire

Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra Business Wire

Sparkol Launches VideoScribe 318.10.2017 13:24Pressemelding

Introducing VideoScribe Version 3 by Sparkol. Already used by over two million people across the world to create engaging explainer videos, Version 3 of the highly intuitive software comes packed full of new features, including: An improved user experience and slick UI - animate easier than ever before Enhanced search - find exactly the image you need in record time Intelligent image recommendations - focus your creativity on your video instead Smoother performance - maximum productivity when using the software VideoScribe customers include the world’s largest brands (HP, BBC, Sky and the University of British Columbia), businesses across every sector, leading education providers, award-winning teachers, charities, campaigners, and coun

Piraeus Bank: Agreement for the Sale of Serbian Operations18.10.2017 13:06Pressemelding

Piraeus Bank announces that it has entered into an agreement to sell its Serbian banking and leasing operations to Direktna Banka A.D., a local Serbian banking group that has been strongly growing its presence in the market, for a total cash consideration between €58mn up to €61mn, depending on the financial performance of the divested assets until completion of the transaction, through a combination of direct sale price and simultaneous reduction of capital in Piraeus Bank Beograd AD. The transaction is conditional upon the usual corporate and regulatory approvals, including those of the National Bank of Serbia and the Hellenic Financial Stability Fund. The transaction represents another step towards the implementation of Piraeus Bank’s Restructuring Plan commitments, as those were agreed with the Directorate General of Competition of the European Commission. The transactio

Introducing InVision Studio, The World’s Most Powerful Screen Design Tool18.10.2017 13:01Pressemelding

InVision, the product design platform powering the world’s best digital experiences, today introduced Studio, a powerful new tool that will change the way screen design is done. InVision Studio was created by working closely with the world’s best design teams and finding inspiration in how they create beloved digital products. The launch of Studio comes at a time when modern organizations are shaping and redefining entire markets through their focus on digital customer experience. InVision already powers the product design process of more than 3 million people at tens of thousands of companies, including eighty percent of the Fortune 100 and brands like Airbnb, Uber, HBO, Amazon, IBM, Nike, and Slack. This new product reflects a major evolution of the digital product design workflow. With Studio, InVision has developed an end-to-end platform for designing digit

SmartStream and Credit Suisse Expand their Agreement from the Processing of Invoices and Reconciliations to Now Include Listed Derivatives Brokerage Fees18.10.2017 12:00Pressemelding

SmartStream Technologies, the financial Transaction Lifecycle Management (TLM®) solutions provider, today announced that its original agreement with Credit Suisse was recently expanded to include the processing of Listed Derivatives Brokerage fees which began in February of this year. This expansion in SmartStream’s partnership with Credit Suisse complements its existing managed service solution for the processing of invoices and reconciliations within Credit Suisse’s OTC Fixed Income Derivatives, US Listed Equity Options and Cash Equities businesses across brokerage, clearing and exchange fees operations, which began in June of 2016. The managed service enables the bank to advance the operational efficiencies created through the use of the utility-based solutions offered by SmartStream, utilizing their proprietary execution fees and expense management software. By centralizing the ent

Biogen Confirms Commitment to Tackle Multiple Sclerosis Through Comprehensive Approach18.10.2017 11:30Pressemelding

Biogen (NASDAQ: BIIB) confirms its comprehensive approach to tackle multiple sclerosis (MS) at the seventh Joint Meeting of the European Committee for Treatment and Research in MS and Americas Committee for Treatment and Research in MS (ECTRIMS-ACTRIMS; 25 – 28 October). “With more than 25 years of scientific leadership in MS, Biogen’s commitment is unwavering,” said Michael Ehlers, executive vice president, Research & Development at Biogen. “Our expertise puts Biogen in a unique position with a comprehensive approach including active research and clinical development on how to repair the damage to the central nervous system from relapsing forms of MS, a portfolio of new drug candidates that we are advancing to the clinic, our collaboration to identify a digital biomarker, our focus to advance understanding of the disease through global data collection with MS PATHS, active pursuit

Scientist.com Collaborates With UKCRC Tissue Directory and Coordination Centre to Ensure Quality of Human Biosample Acquisition Globally18.10.2017 11:01Pressemelding

Scientist.com, the world’s leading marketplace for outsourced scientific services, today announced that it is entering into a collaboration with the UKCRC Tissue Directory and Coordination Centre (UKCRC TDCC) to support the work of biobanks throughout the United Kingdom. The partnership will enable drug R&D to move forward more quickly by making large collections of prescreened human biological samples available for scientific research. Through the new COMPLI™ feature, Scientist.com provides a simple, efficient and effective way of increasing the visibility and accessibility of biobanks’ human biological samples collections, which support new medical research. COMPLI™ introduces a common, comprehensive process and supply agreement supporting access to human biosamples. The goal is to enable biobanks to more easily connect with researchers in the pharmaceutical and biotech indust

I vårt presserom finner du alle våre siste saker, kontaktpersoner, bilder, dokumenter og annen relevant informasjon om oss.

Besøk vårt presserom